Lumos Diagnostics Holdings Ltd
Research Lumos Diagnostics Holdings Ltd (LDX) on Bullrun: market cap AUD 99.16M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLDX
- ExchangeAU
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyAUD
- Market capAUD 99.16M
- Financial periodFY2025
- RevenueUSD 12.50M
- Revenue growth12.3%
- Net income-USD 7.18M
- Free cash flow-USD 9.39M
- Gross margin63.2%
Valuation Snapshot
latest market cap is AUD 99.16M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 12.50M | -USD 7.18M | -USD 9.39M | 63.2% | -0.01 | USD 1.96M | USD 6.99M | USD 6.16M |
| FY2024 | USD 11.13M | -USD 8.59M | USD 848.00K | 63.8% | -0.02 | USD 6.48M | USD 8.06M | USD 7.11M |
| FY2023 | USD 10.54M | -USD 8.97M | -USD 9.79M | 56.7% | -0.04 | USD 3.02M | USD 9.79M | USD 9.50M |
| FY2022 | USD 11.63M | -USD 45.72M | -USD 22.39M | 38.3% | -0.28 | USD 7.98M | USD 7.19M | USD 17.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 99.16M | n/a | n/a | n/a |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lumos Diagnostics Holdings Ltd's market cap?
Lumos Diagnostics Holdings Ltd's market capitalization is AUD 99.16M.
What does Lumos Diagnostics Holdings Ltd do?
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.